Can I switch from Evorel 75 µg transdermal patches to Estradot patches, and what dosing should be used?

Can You Switch from Evorel 75 to Estradot Patches?

Yes, you can switch from Evorel 75 µg patches to Estradot patches, but you should use the Estradot 75 µg patch to maintain equivalent estradiol delivery. Both are transdermal 17β-estradiol matrix patches, but they may have different bioavailability profiles that require attention during the transition.

Key Considerations for the Switch

Dose Equivalency

• Evorel 75 delivers 75 µg of estradiol per 24 hours
• Switch to Estradot 75 µg (10.0 cm² patch) to maintain the same nominal delivery rate 1
• Both patches contain 17β-estradiol and use matrix technology, making them therapeutically interchangeable in principle

Important Bioavailability Differences

Critical caveat: Research demonstrates that patches with identical labeling can deliver significantly different amounts of estradiol into the bloodstream. A comparative study showed that two similarly labeled 50 µg patches (Evorel vs. another matrix system) produced markedly different estradiol exposure, with one delivering approximately 35% less estradiol than the other 2. This means:

• Monitor for symptom recurrence in the first 4-8 weeks after switching
• If menopausal symptoms return or worsen, the Estradot may be delivering less estradiol than your previous Evorel patch
• Conversely, watch for estrogen excess symptoms (breast tenderness, bloating, breakthrough bleeding)

Practical Switching Protocol

1. Direct substitution approach:

   • Remove your current Evorel 75 patch at its scheduled change time
   • Apply Estradot 75 µg patch immediately
   • Maintain your usual twice-weekly application schedule (both are changed every 3-4 days)

2. Clinical monitoring (weeks 1-8):

   • Track vasomotor symptoms (hot flashes, night sweats)
   • Note any new side effects or skin reactions
   • Document breakthrough bleeding if you have a uterus and use progestogen

3. Dose adjustment if needed:

   • If symptoms persist after 4-6 weeks, consider increasing to Estradot 100 µg
   • If estrogen excess symptoms develop, consider reducing to Estradot 50 µg
   • The dose should be individualized based on symptom control, not arbitrary estradiol levels 3

Progestogen Considerations

If you have a uterus and currently take progestogen with your Evorel:

• Continue your current progestogen regimen unchanged during the switch 3
• Acceptable options include medroxyprogesterone acetate (2.5 mg daily or 5 mg for 10-14 days/month), micronized progesterone (100 mg daily or 200 mg for 10-14 days/month), or norethindrone acetate 3
• Micronized progesterone is preferred when available due to better cardiovascular and thromboembolism risk profile 4

Patch Application and Adherence

Both Estradot and Evorel demonstrate good adherence properties 1, 5:

• Apply to clean, dry, intact skin on lower abdomen or buttocks
• Rotate application sites to minimize skin irritation
• Change patches twice weekly (every 3-4 days)
• Estradot patches have been shown to adhere well with minimal skin irritation 1

When to Measure Estradiol Levels

Routine estradiol monitoring is not necessary for most women 3. However, consider checking serum estradiol if:

• Symptoms fail to improve despite dose escalation
• You're using higher than standard doses
• There's concern about poor absorption (approximately 25% of women on highest licensed doses have subtherapeutic levels) 6

Advantages of Transdermal Estradiol

Both patches avoid first-pass hepatic metabolism, which is particularly beneficial if you have 3, 7:

• Hypertension
• Hypertriglyceridemia
• History of venous thromboembolism (VTE) risk
• Obesity or metabolic syndrome
• Diabetes
• History of gallbladder disease

Common Pitfalls to Avoid

• Don't assume identical labeling means identical delivery - bioavailability can differ between brands 2
• Don't measure FSH to monitor adequacy - FSH remains elevated in menopause regardless of adequate estrogen replacement 3
• Don't continue patches if severe skin reactions develop - switch to oral or gel formulations if needed 4
• Don't forget endometrial protection - if you have a uterus, progestogen is mandatory to prevent endometrial hyperplasia 3

Reassess the need for continued therapy every 3-6 months using the lowest effective dose that controls your symptoms 8.